Aptus Capital Advisors’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Aptus Capital Advisors’s Portfolio PJP Stock Details PJP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.4K	Buy	206 +1	+0.5%	+$108	﹤0.01%	1492
2026 Q1	$21.3K	Hold	205	–	–	﹤0.01%	1393
2025 Q4	$21.4K	Buy	205 +1	+0.5%	+$101	﹤0.01%	1404
2025 Q3	$18.9K	Hold	204	–	–	﹤0.01%	1356
2025 Q2	$16.3K	Buy	204 +1	+0.5%	+$80	﹤0.01%	1316
2025 Q1	$17.6K	Buy	203 +1	+0.5%	+$85	﹤0.01%	1229
2024 Q4	$16.7K	Hold	202	–	–	﹤0.01%	1237
2024 Q3	$17.6K	Buy	202 +1	+0.5%	+$86	﹤0.01%	1053
2024 Q2	$16.5K	Hold	201	–	–	﹤0.01%	992
2024 Q1	$16.1K	Buy	201 +1	+0.5%	+$77	﹤0.01%	993
2023 Q4	$15.2K	Buy	200 +25	+14%	+$1.79K	﹤0.01%	768
2023 Q3	$12.7K	Hold	175	–	–	﹤0.01%	784
2023 Q2	$13.2K	Buy	+175	New	+$13.4K	﹤0.01%	678
2023 Q1	–	Sell	-175	Closed	-$13.8K	–	863
2022 Q4	$13.8K	Hold	175	–	–	﹤0.01%	675
2022 Q3	$12K	Buy	+175	New	+$13.1K	﹤0.01%	648

Other funds holding PJP

PAM

Peak Asset Management Louisville, Colorado $680M AUM 22.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MML Investors Services Springfield, Massachusetts $49B AUM 25.55% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

JGCM

Joseph Group Capital Management Columbus, Ohio $476M AUM 21.21% 1-Year Est. Return

Aptus Capital Advisors's PJP Position: Q2 2026 in Review

Aptus Capital Advisors increased its Invesco Pharmaceuticals ETF (PJP) stake by 0.49% in Q2 2026, buying an estimated $108 and bringing the position to 206 shares worth $24.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1492.

Aptus Capital Advisors first reported a position in PJP in Q3 2022 and has held it in 15 quarters since. 117 funds tracked by Wall St. Rank hold PJP as of Q2 2026.

Aptus Capital Advisors held 206 shares of Invesco Pharmaceuticals ETF worth $24.4K as of Q2 2026.
Aptus Capital Advisors bought 1 Invesco Pharmaceuticals ETF share in Q2 2026, an estimated $108.
Invesco Pharmaceuticals ETF made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #1492 holding.
Aptus Capital Advisors first reported a position in Invesco Pharmaceuticals ETF in Q3 2022 and has held it in 15 quarters since.
117 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.